dermal hypersensitivity reaction to semaglutide Semaglutide-induced fixed drug eruption Hypersensitivity to glucagon‐like peptide‐1 receptor

Mol Metab 5 , 834843, (2016)

El programa fase 3 TRIUMPH se encuentra en curso al momento de redaccin, con desenlaces previstos en reduccin ponderal sostenida (TRIUMPH-1, NCT05929066), control glucmico en diabetes (TRIUMPH-2), apnea obstructiva del sueo (TRIUMPH-3) y desenlaces cardiovasculares (TRIUMPH-Outcomes)

At the end of one year, the semaglutide group showed a 2.6% reduction in hip bone mineral density and a 2.1% reduction at the lumbar spine compared to the placebo group - with increased bone resorption markers and no compensatory increase in bone formation

Neuroscience: The compound is explored for its neuroprotective properties, aiding in the investigation of neurodegenerative diseases and potential therapeutic strategies